Abstract
Vascular endothelial growth factor (VEGF) plays an important role in tumour angiogenesis. VEGF binds to tyrosine kinase receptors, which are expressed almost exclusively on tumour endothelium. Therefore, VEGF can be used to target toxin molecules to tumour vessels for anti-angiogenic therapy. However, recent evidence suggests that VEGF can also bind in an isoform-specific fashion to a newly identified neuropilin-1 (NP-1) receptor. NP-1 is widely expressed in normal tissue and presents a potential target for unwanted toxicity. As a consequence, we investigated whether the VEGF121 isoform, which lacks the NP-1 binding domain, could be used to target toxin polypeptides to tumour vasculature. Treatment of endothelial cells with a VEGF121–diphtheria toxin (DT385) conjugate selectively inhibited proliferating endothelial cells, whereas confluent cultures were completely resistant to the construct. In addition, VEGF121–DT385 conjugate treatment completely prevented tumour cell induced angiogenesis in vivo. Most importantly, the conjugate inhibited tumour growth in athymic mice and induced tumour-specific vascular damage. There was also no apparent toxicity associated with the treatment. Our results suggest that proliferating endothelial cells are highly sensitive to VEGF121–toxin conjugates and that the binding to NP-1 receptors is not necessary for efficient inhibition of tumour growth. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arora N, Masood R, Zheng T, Cai J, Smith DL and Gill PS (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59: 183–188
Baillie CT, Winslet MC and Bradley NJ (1995) Tumour vasculature–a potential therapeutic target. Br J Cancer 72: 257–267
Burrows FJ and Thorpe PE (1993) Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA 90: 8996–9000
Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES and Thorpe PE (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagnosis and therapy. Clin Cancer Res 1: 1623–1634
Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45: 136–139
Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF and Dvorak AM (2000) Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumours and adenoviral vectors. J Histochem Cytochem 48: 545–556
Folkman J (1992) The role of angiogenesis in tumour growth. Semin Cancer Biol 3: 65–71
Fulcher S, Lui GM, Houston LL, Ramakrishnan S, Burris T, Polansky J and Alvarado J (1988) Use of immunotoxin to inhibit proliferating human corneal endothelium. Invest Ophthalmol Vis Sci 29: 755–759
Gho YS, Lee JE, Oh KS, Bae DG and Chae CB (1997) Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res 57: 3733–3740
Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi BZ and Neufeld G (1996) Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271: 5519–5523
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD and Wiegand SJ (1999) Vessel cooption, regression, and growth in tumours mediated by angiopoietins and VEGF. Science 284: 1994–1998
Iruela-Arispe ML and Dvorak HF (1997) Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost 78: 672–677
Jain RK (1998) Delivery of molecular and cellular medicine to solid tumours. J Controlled Release 53: 49–67
Lappi DA (1995) Tumour targeting through fibroblast growth factor receptors. Semin Cancer Biol 6: 279–288
Mohanraj D, Olson T and Ramakrishnan S (1995) A novel method to purify recombinant vascular endothelial growth factor (VEGF121) expressed in yeast. Biochem Biophys Res Commun 215: 750–756
Mohanraj D, Wahlsten JL and Ramakrishnan S (1996) Expression and radiolabeling of recombinant proteins containing a phosphorylation motif. Protein Expr Purif 8: 175–182
Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13: 9–22
Olson TA, Mohanraj D, Roy S and Ramakrishnan S (1997) Targeting the tumour vasculature: inhibition of tumour growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 73: 865–870
Plate KH, Breier G, Millauer B, Ullrich A and Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumour angiogenesis. Cancer Res 53: 5822–5827
Plate KH and Risau W (1995) Angiogenesis in malignant gliomas. Glia 15: 339–347
Ramakrishnan S, Fryxell D, Mohanraj D, Olson M and Li BY (1992) Cytotoxic conjugates containing translational inhibitory proteins. Annu Rev Pharmacol Toxicol 32: 579–621
Ramakrishnan S, Olson TA, Bautch VL and Mohanraj D (1996) Vascular endothelial growth factor–toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324–1330
Seon BK, Matsuno F, Haruta Y, Kondo M and Barcos M (1997) Long-lasting complete inhibition of human solid tumours in SCID mice by targeting endothelial cells of tumour vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 3: 1031–1044
Soker S, Fidder H, Neufeld G and Klagsbrun M (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumour cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271: 5761–5767
Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H and Klagsbrun M (1997) Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 272: 31582–31588
Soker S, Takashima S, Miao HQ, Neufeld G and Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumour cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735–745
Veikkola T and Alitalo K (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9: 211–220
Wild R, Ramakrishnan S, Sedgewick J and Griffioen AW (2000) Quantitative assessment of angiogenesis and tumour vessel architecture by computer assisted digital image analysis: effects of VEGF–toxin conjugate on tumour microvessel density. Microvasc Res 59: 368–376
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wild, R., Dhanabal, M., Olson, T. et al. Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer 83, 1077–1083 (2000). https://doi.org/10.1054/bjoc.2000.1439
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1439
Keywords
This article is cited by
-
Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells
Nature Reviews Clinical Oncology (2017)
-
Tumour vasculature targeting agents in hybrid/conjugate drugs
Angiogenesis (2013)
-
Angiogenesis in normal and neoplastic ovaries
Angiogenesis (2005)
-
Angiogenesis, lymphangiogenesis, and melanoma metastasis
Oncogene (2003)
